BRCA1 methylation: A significant role in tumour development?

Seminars in Cancer Biology

Volumn 12, Issue 5, 2002, Pages 359-371

  Catteau, Aurélie ^a   Morris, Joanna R ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

BRCA1 promoter; Breast cancer; Methylation; Ovarian cancer

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CARCINOGENESIS; CPG ISLAND; DNA METHYLATION; GENE LOCUS; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR CLONING; NONHUMAN; OVARY CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE;

EID: 0036389638     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00056-1     Document Type: Article

References (105)

1. Dobovric A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57:3347-3350
2. Easton D, Peto J (1990) The contribution of inherited predisposition to cancer incidence. Cancer Surv 9:395-416
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
4. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC (1994) Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8:399-404
5. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
6. Iau PT, Macmillan RD, Blamey RW (2001) Germ line mutations associated with breast cancer susceptibility. Eur J Cancer 37:300-321
7. Kelsell DP, Black DM, Bishop DT, Spurr NK (1993) Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. Hum Mol Genet 2:1828-1832
8. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9:439-443
9. Smith SA, Easton DF, Evans DGR, Ponder BAJ (1992) Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 2:128-131
10. Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171-182
11. Kerr P, Ashworth A (2001) New complexities for BRCA1 and BRCA2. Curr Biol 11:R668-R676
12. Shen S-X, Weaver Z, Xu X, Li C, Weinstein M, Chen L, Guan X-Y, Ried T, Deng C-X (1998) A targeted disruption of the murine BRCA1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17:3115-3124
13. Foray N, Randrianarison V, Mrot D, Perricaudet M, Lenoir G, Feunteun J (1999) Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene 18:7334-7342
14. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng C-X (1999) Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43
15. Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) BRCA1 controls homology-directed DNA repair. Mol Cell 4:511-518
16. Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M (2001) From the cover: direct DNA binding by BRCA1. Proc Natl Acad Sci USA 98:6086-6091
17. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A et al. (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227
18. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA (1997) p53 mutations in BRCA1-associated familial breast cancer. Lancet 350:638-639
19. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC, Deng CX (2001) Genetic interactions between tumor suppressors BRCA1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28:266-271
20. Chapman MS, Verma IM (1996) Transcriptional activation by BRCA1. Nature 382:678-679
21. Monteiro ANA, August A, Hanafusa H (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93:13595-13599
22. Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH (2000) Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6:757-768
23. Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H (1998) BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95:2302-2306
24. Fan S, Wang J-A, Yuan R, Ma Y, Meng Q, Erdos MR, Pestall RG, Yuan F, Auborn KJ, Goldberg ID et al. (1999) BRCA1 inhibition of oestrogen receptor signaling in transfected cells. Science 284:1354-1356
25. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ et al. (2002) p300 Modulates the BRCA1 inhibition of oestrogen receptor activity. Cancer Res 62:141-151
26. Liu H-X, Caartegni L, Zhang MQ, Krainer AR (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27:55-58
27. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC (1996) Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 6:1029-1049
28. Puget N, Torchard D, Serovasinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S (1997) A 1-kb alu-mediated germ-line deletion removing BRCA1 exon-17. Cancer Res 57:828-831
29. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FBL, Hageman S, Arts PJW, Lightenberg MJL et al. (1997) BRCA1 genomic deletions are major founder mutations in Duch breast cancer patients. Nat Genet 17:341-345
30. Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, Lenoir GM, Mazoyer S, Weber BL (2000) Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841-850
31. Gad S, Scheuner MT, Pages-Berhouet S, Caux-Moncoutier V, Bensimon A, Aurias A, Pinto M, Stoppa-Lyonnet D (2001) Identification of a large rearrangement of the BRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing. J Med Genet 38:388-392
32. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122
33. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A (1995) A somatic BRCA1 mutation in an ovarian tumor. Nat Genet 9:343-344
34. Khoo US, Ozcelik H, Cheung AN, Chow LW, Ngan HY, Done SJ, Liang AC, Chan VW, Au GK, Ng WF et al. (1999) Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 18:4643-4646
35. van der Looij M, Cleton-Jansen AM, van Eijk R, Morreau H, van Vliet M, Kuipers-Dijkshoorn N, Olah E, Cornelisse CJ, Devilee P (2000) A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1. Genes Chromosomes Cancer 27:295-302
36. Cropp CS, Champeme MH, Liderau R, Cllahan R (1993) Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. Cancer Res 53:5617-5619
37. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y (1993) Detailed deletion mapping of chromosome 17q in ovarian. Cancer Res 53:3382-3385
38. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1 mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692-695
39. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444-450
40. Sourvinos G, Spandinos DA (1998) Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 245:75-80
41. Magdinier F, Ribierias S, Lenoir G, Frappart L, Dante R (1998) Down-regulation of BRCA1 in human sporadic breast cancer: analysis of DNA methylation patterns of the putative promoter region. Oncogene 17:3169-3176
42. Oczelik H, To M, Couture J, Bull S, Andrulis I (1998) Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int J Cancer 77:1-6
43. Russel P, Pharoah P, De Foy K, Ramus S, Symmonds L, Wislon A, Scott I, Ponder B, Gayther S (2000) Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 87:317-321
44. Catteau A, Xu CF, Brown MA, Hodgson S, Greenman J, Mathew CG, Dunning AM, Solomon E (1999) Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions. Br J Cancer 79:759-763
45. Wilson C, Ramos L, Villasenor M, Anders K, Press M, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236-240
46. Budhram-Mahadeo V, Ndisang D, Ward T, Weber BL, Latchman DS (1999) The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. Oncogene 18:6684-6691
47. Blagosklonny MV, An WG, Melillo G, Nguyen P, Trepel JB, Neckers LM (1999) Regulation of BRCA1 by protein degradation. Oncogene 18:6460-6468
48. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321:209-213
49. Larsen F, Gundersen G, Prydz H (1992) Choice of enzymes for mapping based on CpG islands in the human genome. GATA 9:80-85
50. Bird A, Taggart M, Frommer M, Miller OJ, Macleod D (1985) A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. Cell 40:91-99
51. Bird A (1992) The essentials of DNA methylation. Cell 70:5-8
52. Feinberg A, Gehrke C, Kuo K, Ehrlich M (1988) Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 48:1159-1161
53. Clark S, Harrison J, Molloy P (1997) Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 195:67-71
54. Prendergast G, Ziff E (1991) Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science 251:186-189
55. Asiedu CK, Scotto L, Assoian RK, Ehrlich M (1994) Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-beta 1 gene. Biochim Biophys Acta 1219:55-63
56. Zhang X, Ehrlich K, Wang R, Ehrlich M (1986) Effect of site specific DNA methylation and mutagenesis on recognition by methylated DNA-binding protein from human placenta. Nucleic Acid Res 14:8387-8397
57. Kass SU, Pruss D, Wolffe AP (1997) How does DNA methylation repress transcription? Trends Genet 13:444-449
58. Bestor TH (1998) Gene silencing. Methylation meets acetylation. Nature 393:311-312
59. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187-191
60. Rountree MR, Bachman KE, Herman JG, Baylin SB (2001) DNA methylation, chromatin inheritance, and cancer. Oncogene 20:3156-3165
61. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389
62. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP (1991) Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48:880-888
63. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15ink4B1. Cancer Res 56:722-727
64. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan D-S, Gnarra JR, Linehan M et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704
65. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE, Sidransky D, Baylin SB (1995) Inactivation of the cdkn2/p16/mts1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530
66. Hiltunen MO, Alhonen L, Koistinaho J, Myohanen S, Paakkonen M, Marin S, Kosma VM, Janne J (1997) Hypermethylation of the APC (Adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma. Int J Cancer 70:644-648
67. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163-167
68. Costello JF, Plass C (2001) Methylation matters. J Med Genet 38:285-303
69. Yang X, Yan L, Davidson NE (2001) DNA methylation in breast cancer. Endocr Relat Cancer 8:115-127
70. Xu C-F, Brown MA, Chambers JA, Griffiths B, Nicolai H, Solomon E (1995) Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet 4:2259-2264
71. Brown MA, Xu C-F, Nicolai H, Griffiths B, Chambers JA, Black D, Solomon E (1996) The 5′ end of the BRCA1 gene lies within a duplicated region of human-chromosome 17q21. Oncogene 12:2507-2513
72. Xu C-F, Chambers JA, Solomon E (1997) Complex regulation of the BRCA1 gene. J Biol Chem 272:20994-20997
73. Thakur S, Croce CM (1999) Positive regulation of the BRCA1 promoter. J Biol Chem 274:8837-8843
74. Suen T-C, Goss PE (1999) Transcription of BRCA1 is dependent on the formation of a specific protein-DNA complex on the mininal BRCA1 bi-directional promoter. J Biol Chem 274:31297-31304
75. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
76. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes C, Repasky EA et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569
77. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A (2000) Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21:147-151
78. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, Longy M, Guinebretiere JM, Sauvan R, Noguchi T et al. (1998) Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 58:1588-1592
79. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510
80. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW (2000) Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761-1765
81. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329-5333
82. Niwa Y, Oyama T, Nakajima T (2000) BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Jpn J Cancer Res 91:519-526
83. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer TK (1998) CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16:1161-1169
84. Rice JC, Massey-Brown KS, Futscher BW (1998) Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17:1807-1812
85. Rice JC, Futscher BW (2000) Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res 28:3233-3239
86. Magdinier F, Billard LM, Wittmann G, Frappart L, Benchaib M, Lenoir GM, Guerin JF, Dante R (2000) Regional methylation of the 5′ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J 14:1585-1594
87. DiNardo DN, Butcher DT, Robinson DP, Archer TK, Rodenhiser DI (2001) Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene 20:5331-5340
88. Atlas E, Stramwasser M, Mueller CR (2001) A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element. Oncogene 20:7110-7114
89. Catteau A, Harris WH, Xu C-F, Solomon E (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18:1957-1965
90. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S et al. (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001-3007
91. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD (2001) TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092-4097
92. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP et al. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548
93. Olopade OI, Grushko T (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:2028-2029
94. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-752
95. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF (1997) Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 277:1996-2000
96. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138
97. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH (2000) CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 6:1432-1438
98. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Caldwell CW, Huang TH (2001) Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res 61:8375-8380
99. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE et al. (2001) Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357:1335-1336
100. Welcsh PL, King M-C (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713
101. Toyota M, Issa JP (2000) The role of DNA hypermethylation in human neoplasia. Electrophoresis 21:329-333
102. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B (1999) The protective effect of oestrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic Vitamin D receptor. Oncol Res 11:255-264
103. Klein CB, Costa M (1997) DNA methylation, heterochromatin and epigenetic carcinogens. Mutat Res 386:163-180
104. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687-692
105. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20:8215-8235